Blue Jet Healthcare Limited — PPTs, 14-05-2025: Investor Presentation

1. Financial Highlights:

Blue Jet Healthcare posted Q4 revenue of Rs. 340.4 Cr, up 6.9% QoQ and 85.1% YoY, driven by pharmaceutical intermediates. EBITDA hit a record Rs. 140 Cr with a 41.1% margin, expanding 216 bps QoQ and 1226 bps YoY. PAT surged 177.7% YoY to Rs. 110.1 Cr, with a margin of 32.3%. FY25 revenue rose 44.7% to Rs. 1030 Cr, EBITDA increased 64.8% to Rs. 377.7 Cr (margin 36.7%), and PAT grew 86.4% to Rs. 305.2 Cr, with margin expansion of 662 bps. Cash and treasury investments stand at Rs. 28.48 Cr.

2. Strategic Initiatives & Growth Drivers:

Capacity expansion is underway, including a new 30,366 sq. mts plot at Dahej costing Rs. 11.12 Cr. The company is advancing integration into gadolinium-based contrast media intermediates, backed by strong R&D. Commercialization of these products began in Q4. Continued focus on operational efficiencies, cost optimization, and R&D investments targets chronic therapeutic areas and niche pharma intermediates.

3. Business Developments:

Board approval secured for capital raising up to Rs. 1500 Cr via QIP or preferential issuance (pending shareholder approval). The portfolio now includes 51 commercialized products across three key segments. Long-term supply contracts (4-26 years) with leading contrast media makers provide business stability.

4. Market Position & Competitive Advantage:

Blue Jet is a leading Indian supplier of contrast media intermediates, with over 75% export share of a key molecule. Serving over 300 global customers in high-intensity sweeteners and strong ties with pharma innovators underpin scale. Product quality, expertise in complex chemistry, and longstanding relationships create high barriers to entry and revenue visibility.

5. Investor Implications:

Strong financial momentum, margin gains, and capacity expansions signal positive growth potential. Forward integration into high-value pharma segments supports sustainable profitability. Execution of capacity ramp-up, capital raise success, and maintaining market leadership remain key factors to monitor.